EGFR and hepatocellular carcinoma: Sorafenib, which acts as a multiple tyrosine kinase inhibitor, is a mainstream molecular targeted drug approved for HCC treatment.14, 15, 16 Previous studies have identified multiple mechanisms underlying reduced sensitivity to sorafenib in HCC,17 including various molecular and signalling pathway alterations such as activation of the EGFR pathway,18 epithelial mesenchymal transition19 and induction of autophagy.20, 21 Demonstrations of the efficacy of targeted molecular therapies have triggered the search for additional molecules with therapeutic potential in HCC.